Fragmento

Aplastic anemia is rare hematopoietic stem cell disorder that results in pancytopenia and a hypocellular bone marrow. The pathophysiology of acquired aplastic anemia is usually immune-mediated, with autoreactive lymphocytes mediating the destruction of hematopoietic stem cells. Aplastic anemia has a varied clinical course; some patients have mild symptoms that require little or no therapy, whereas others present with severe pancytopenia representing a medical emergency. Definitive treatment options for severe aplastic anemia (SAA) include allogeneic bone marrow transplantation (BMT), immunosuppressive therapy (usually antithymocyte globulin and cyclosporine, ATG/CsA), and high dose cyclophosphamide therapy (HiCY). The advantages and disadvantages of these therapies for SAA will be discussed.

Palabras clave:

2013-07-08   |   556 visitas   |   Evalua este artículo 0 valoraciones

Vol. 12 Núm.1. Abril-Mayo 2011 Pags. S81-S83 Rev Hematol 2011; 12(Supl. 1)